FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

May 27th 2022

Kristi Rosa

The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

FDA Approves 2 Frontline Nivolumab-Based Regimens for Unresectable Advanced or Metastatic ESCC

May 27th 2022

Kristi Rosa

The FDA has approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, irrespective of PD-L1 status.

Uliledlimab/Toripalimab Combo Demonstrates Efficacy and Safety in Advanced NSCLC

May 27th 2022

Uliledlimab in combination with toripalimab generated notable response rates in patients with advanced non–small cell lung cancer who were previously ineligible to receive standard-of-care treatment.

SIR-Spheres® Y-90 Resin Microspheres Provide Increased Survival Benefit in Colorectal Cancer

May 27th 2022

Ashling Wahner

Mike Cusnir, MD, discusses the role of Y-90 maintenance therapy in colorectal cancer and how it can supplement chemotherapy to prolong life and reduce adverse effects.

Fox Chase Cancer Center Experts Highlight the Growing Treatment Landscapes in Lung Cancer

May 27th 2022

Ryan Scott

Multiple FDA-approved frontline immunotherapy options have continued to shape the treatment paradigm in non–small cell lung cancer. Additionally, more knowledge regarding the effects of immunotherapy on certain driver mutations has helped drive therapy decisions across lines of treatment.